Products

HUMIRA (adalimumab injection)

^PrHUMIRA^® is indicated for, in combination with methotrexate (MTX), reducing the signs and symptoms of moderately to severely active polyarticular JIA in patients, 2 years of age and older who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). HUMIRA can be used as monotherapy in case of intolerance to MTX or when continued treatment with MTX is not appropriate. HUMIRA has not been studied in pediatric patients with polyarticular JIA aged less than 2 years.
 

^PrHUMIRA^® is indicated for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
 

RINVOQ (upadacitinib)

^PrRINVOQ^® is indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to MTX. RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic DMARDs.
 

^PrRINVOQ^® is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to MTX or other DMARDs. RINVOQ may be used as monotherapy or in combination with MTX.
 

^PrRINVOQ^® is indicated for the treatment of adults with active AS (radiographic axial spondyloarthritis) who have had an inadequate response to a biologic DMARD or when use of those therapies is inadvisable. RINVOQ may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs (NSAIDs).